Vero vs. MDCK Cells: Comparative Use in Vaccine Manufacturing within Cell Factory

 Vaccine manufacturing relies heavily on well-characterized cell substrates that can support efficient virus propagation, process scalability, and regulatory compliance. Among adherent cell lines, Vero and MDCK cells are two of the most widely used platforms in viral vaccine production. Each cell line offers distinct biological and process-related advantages, particularly when cultured in Cell Factory systems designed for large-scale adherent cell expansion.

Understanding the differences between Vero and MDCK cells is essential for selecting the most suitable upstream strategy, especially when transitioning from laboratory development to industrial manufacturing using Multilayer Cell Factory platforms.

Cell Factory 10 Layers TC-treated

1. Overview of Vero and MDCK Cells in Vaccine Production

Vero Cells

Vero cells, derived from African green monkey kidney epithelial cells, are one of the most established cell substrates in vaccine manufacturing. They are widely used for producing:

Inactivated and live-attenuated viral vaccines

Viral antigens for human and veterinary vaccines

Emerging viral vaccines requiring high biosafety control

Vero cells exhibit robust adherence and stable growth behavior, making them well suited for large-scale culture in cell factory systems.

MDCK Cells

MDCK (Madin-Darby Canine Kidney) cells are epithelial cells commonly associated with influenza vaccine production. Their key applications include:

Seasonal and pandemic influenza vaccines

Influenza virus seed amplification

Cell-based alternatives to egg-based vaccine production

MDCK cells are known for their strong virus yield potential, particularly for influenza strains, and adapt well to controlled adherent culture environments.

2. Growth Characteristics in Cell Factory Systems

Both Vero and MDCK cells grow as adherent monolayers, making them compatible with Cell Factory platforms. However, their growth behavior differs in ways that affect process design:

Vero cells demonstrate consistent attachment and uniform monolayer formation across large surface areas, supporting predictable scale-up in multilayer formats.

MDCK cells often show faster proliferation rates, but may require more precise control of seeding density and culture conditions to maintain uniformity across layers.

Multilayer Cell Factory provide the large surface area and environmental stability required to support both cell types at industrial scale.

Closed System Cell Factory with Tube

3. Virus Production Performance

Vero Cells

Vero cells support the replication of a broad range of viruses, including:

Poliovirus

Rabies virus

Measles virus

Emerging viral pathogens

Their versatility makes them a preferred choice for manufacturers developing multiple vaccine platforms within the same production facility.

MDCK Cells

MDCK cells are particularly optimized for influenza virus replication and are widely used in:

Cell-based influenza vaccine manufacturing

High-yield virus amplification

Rapid response to strain updates

Their ability to produce high virus titers in adherent systems makes them well suited for high-throughput vaccine production workflows.

4. Scalability and Manufacturing Considerations

When scaling vaccine production, both cell lines benefit from the standardized geometry and reproducibility of Multilayer Cell Factory systems. Key considerations include:

Vero cells are often favored for long production campaigns due to their genetic stability and regulatory track record.

MDCK cells may offer higher productivity for specific viruses but can require tighter process control during scale-up.

Cell Factory help mitigate these challenges by reducing handling steps, improving batch-to-batch consistency, and enabling semi-closed or closed operation.

Cell Factory 40 Layers TC-treated

5. Regulatory and Quality Perspectives

Regulatory acceptance plays a critical role in cell substrate selection:

Vero cells have a long history of regulatory approval across multiple global markets, supporting their use in licensed vaccines.

MDCK cells are also widely accepted, particularly in influenza vaccines, but often require virus- and process-specific validation.

Using standardized cell factory platforms supports regulatory compliance by enabling consistent culture conditions and traceable manufacturing workflows.

6. Choosing the Right Cell Line for Vaccine Manufacturing

The choice between Vero and MDCK cells depends on multiple factors, including:

Target virus type

Desired production scale

Regulatory strategy

Facility capabilities and process design

When combined with Cell Factory or Multilayer Cell Factory systems, both cell lines can support reliable, scalable, and high-quality vaccine production.

Conclusion

Vero and MDCK cells each play a vital role in modern vaccine manufacturing. Vero cells offer versatility, regulatory maturity, and stable large-scale performance, while MDCK cells excel in influenza virus production with high yield potential.